Can-Fite Phase II for Liver Cancer
Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), has initiated a Phase 2 study with its anti-cancer drug CF102, the second drug in its pipeline of A3 adenosine receptor ligands. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). Based on the successful conclusion of a former Phase 1/2 trial, the company developed a Phase 2 protocol that will be conducted under an open IND with the FDA. The study will include 130 patients with an advanced liver cancer disease and CF102 will be given as a standalone drug. The company reported that the Phase 1/2 study data demonstrated that the trial objectives were successfully achieved, demonstrating a very favorable safety profile for CF102 in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis classes A and B. In addition, the median overall survival time was very encouraging given that most patients were treated in the second-line setting and some were Child-Pugh class B. Another finding indicated that the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict the patients’ reaction to treatment with CF102. Interestingly, one of the patients that has been included in the Phase 1/2 study is treated for 4 years with CF102 and is doing very well.